Past catalysts on this ticker, reconciled against the announcement parse pipeline. Hover any row for the parsed outcome detail.
Lenzetto's own upcoming catalysts alongside class-defining historical readouts and upcoming primary completion dates in the same mechanism classes. Each event moves the broader thesis for Lenzetto. Showing past 6 months and next 12 months · 1 later hidden.
Same axes, same units. Discontinued and historical pivotal trials excluded; see Competitor Landscape below for the full set.
| Trial | Sponsor | Class | Phase / Line | Design | Primary endpoint | Dosing | Key eligibility | n |
|---|---|---|---|---|---|---|---|---|
| Lenzetto | Acrux | Drug Delivery Device | Approved | 0 | ||||
| The Effect of Tirzepatide on Menopausal Vasomotor Symptoms and Biological Aging in Post-menopausal Women With Obesity | Mayo Clinic | — |
Read-across commentary attached per trial. Phase ordering preserved within each group.
External analyst notes, journalism, and industry commentary cited with attribution.
"Sponsor guided" dates come from IR materials and earnings calls; hover for the cited source. "CT.gov proxy" dates fall back to the registry primary completion date — actual readouts typically follow by 3-6 months.
| — |
| — |
| — |
| — |
| — |
| Focusing on the Menopausal Transition to Improve Mid-Life Women's Health | University of Colorado, Denver | — | PHASE2/PHASE3 | — | — | — | — | — |
| Phase IIB Trial of Bazedoxifene Plus Conjugated Estrogens | University of Kansas Medical Center | — | Phase 2 | — | — | — | — | — |
| Safety and Efficacy of Asimadoline (TP0052) in Patients With Vasomotor Symptoms (VMS). | Tioga Pharmaceuticals | — | Phase 2 | — | — | — | — | — |
| Proof-of-Concept Trial to Assess the Efficacy and Safety of Fezolinetant in Improving Vasomotor Symptoms in Men With Prostate Cancer Undergoing Androgen Deprivation Therapy | Shehzad Basaria, M.D. | — | Phase 2 | — | — | — | — | — |
| Finding Links Between Hot flASHes and CardioVascular Disease | Massachusetts General Hospital | — | Phase 2 | — | — | — | — | — |